Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study. Issue 3 (8th July 2019)

• Record Type: Journal Article
• Authors: Kishi, Taro; Sakuma, Kenji; Okuya, Makoto; Ninomiya, Kohei; Oya, Kazuto; Kubo, Momoko; Matsui, Yuki; Nomura, Ikuo; Okuyama, Yuji; Matsunaga, Shinji; Iwata, Nakao
• Is Part Of: Neuropsychopharmacology reports. Volume 39:Issue 3(2019)
• Page Start: 252
• Page End: 255
• Publication Date: 2019-07-08
• Subjects: efficacy -- insomnia -- psychiatric disorder -- safety -- suvorexant; Neuropsychopharmacology -- Periodicals; 615.78
• DOI: 10.1002/npr2.12069
• Languages: English
• ISSNs: 2574-173X

Abstract

Abstract: Aim: There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Methods: This one‐week, prospective, single‐arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18–64 or 15 mg if age ≥ 65 years) for insomnia included 57 patients with psychiatric disorders who had experienced any of the following insomnia symptoms for four or more nights during the week prior to the start of the study: total sleep time (TST) <6 hours, time to sleep onset (TSO) ≥30 minutes, or two or more episodes of wake after sleep onset. Results: The mean age of the patients was 49.4 ± 17.3 years; 54.4% were women, 49.1% had a major depressive disorder, and 77.2% completed the trial. Compared with the baseline scores (the mean scores for the two days before the start of the study), taking suvorexant was associated with significant improvements in TST, TSO, wake time after sleep onset, and the patients' sleep satisfaction level at week 1. Adverse events included at least one adverse event (43.9%), sleepiness (28.8%), fatigue (11.5%), nightmares (5.8%), headache (3.8%), dizziness (3.8%), and vomiting (1.9%). Conclusion: Suvorexant was beneficial for the treatment of insomnia in people with psychiatric disorders. However, this study was of short duration and included only a relatively small number of patients. A larger, long‐term study is needed to investigate the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Abstract : This is one‐week, prospective, single‐arm, clinical trial of fixed dose of suvorexant for insomnia included 57 patients with psychiatric disorders. Compared with the baseline scores, taking suvorexant was associated with significant improvements in total sleep time, time to sleep onset, wake time after sleep onset, and the patients' sleep satisfaction level at week 1.